Zamip Patel, MD
Urology · French Camp, CANPI 1437318326
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (43.2%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Intuitive Surgical at 52.6% of the total. 2025 is the largest year on record at $11,666, more than ten times the $294 reported in 2019.
Across 109 payments — averaging $202.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$12K
- Stryker$3K
- Galen US Inc$2K
- Valencia Technologies Corporation$1K
- Boston Scientific$860
- Procept Biorobotics Corporation$847
- plus $4K from 25 others
Across 4 payments — averaging $68,751 each. An ownership or investment interest held by the physician or an immediate family member.
- Valencia Technologies Corporation$275K
What the payments were for
- Consulting fees$4,83322%
- Travel & lodging$2,58812%
- Food & beverage$5,09723%
- Education$9,53243%
- Gifts$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 23 | $11,615 |
| Stryker | 1 | $2,500 |
| Galen US Inc | 2 | $1,500 |
| Valencia Technologies Corporation | 4 | $1,021 |
| Boston Scientific | 12 | $860 |
| Procept Biorobotics Corporation | 7 | $847 |
| BD | 2 | $833 |
| Coloplast | 10 | $678 |
| Astellas Pharma US Inc | 6 | $411 |
| Medtronic(2 entities) | 5 | $366 |
| Teleflex LLC | 3 | $300 |
| Axonics, Inc. | 6 | $216 |
| KARL Storz Endoscopy-america | 2 | $166 |
| Neotract Inc. | 1 | $125 |
| Pacira Pharmaceuticals Incorporated | 1 | $110 |
| Endo Pharmaceuticals Inc. | 5 | $105 |
| Innovation Technologies Inc | 1 | $68 |
| Endo USA, Inc. | 3 | $62 |
| AstraZeneca | 2 | $55 |
| Accord Healthcare, Inc. | 1 | $30 |
| Amgen | 1 | $28 |
| Novartis | 1 | $23 |
| Olympus America Inc. | 1 | $22 |
| Agiliti Surgical, Inc. | 1 | $21 |
| Laborie Medical Technologies Corp. | 1 | $20 |
| Urogen Pharma, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Antares Pharma, Inc. | 1 | $14 |
| Surgenex LLC | 1 | $14 |
| Tolmar, Inc. | 1 | $13 |
| Clarus Therapeutics Inc. | 2 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$9,501
- SYNERA$1,500
- DAVINCI XI$1,500
- eCoin Device Kit$959
- AquaBeam Robotic System$767
- TITAN$352
- rezum Generator$338
- UroLift System$130
- PENILE & TESTICULAR RECONSTRUCTN$127
- UroLift$125
- LithoVue$119
- Barrigel$117
- INTERSTIM$116
- EXPAREL$110
- GENERAL BPH$105
- XTANDI$102
How this compares
$22,064 in reported general payments places this provider in the 85th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 42 | $40,053 |
| Testosterone Cypionate | 64 | $4,451 |
| Desmopressin AcetateDesmopressin (Nonrefrigerated) | 20 | $2,341 |
| Silodosin | 27 | $1,894 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 71 | $1,815 |
| Tamsulosin Hcl | 122 | $1,795 |
| Oxybutynin Chloride ErOxybutynin Chloride | 67 | $1,784 |
| Desmopressin Acetate | 26 | $1,752 |
| NitrofurantoinNitrofurantoin Macrocrystal | 24 | $1,284 |
| Finasteride | 95 | $1,231 |
| Solifenacin Succinate | 18 | $1,047 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 28 | $887 |
| Ciprofloxacin Hcl | 52 | $330 |
| Sildenafil Citrate | 14 | $199 |
| Cephalexin | 16 | $149 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $411 | $40,05342 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,324 urology providers in California.
Other urology in French Camp
- Stephen FreedlandWest Hollywood$1.9M
- Arie BelldegrunLos Angeles$1.8M
- Mihir DesaiLos Angeles$1.5M
- Steven WilsonIndio$1.1M
- Stuart HoldenLos Angeles$1.1M
- Elward CrawfordSan Diego$849K
- Edward UchioOrange$849K
- Victor ChingUpland$809K
- Jaime LandmanOrange$657K
- William AronsonLos Angeles$540K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.